Multivariable analysis in ADEB-treated patients for OS, EFS, and RR.
. | OS from study entry . | EFS from study entry . | RR from end of course 2 . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
n . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | n . | HR . | 95% CI . | P . | |
HSF1-pSer326 | |||||||||||
Low | 52 | 1 | 1 | 48 | 1 | ||||||
Middle | 83 | 2.10 | 0.89-4.95 | .090 | 1.92 | 1.07-3.43 | .028 | 70 | 1.60 | 0.84-3.04 | .156 |
High | 69 | 3.58 | 1.56-8.22 | .003 | 2.94 | 1.65-5.24 | <.001 | 60 | 2.76 | 1.45-5.29 | .002 |
Risk group | |||||||||||
Low | 155 | 1 | 1 | 146 | 1 | ||||||
High | 49 | 2.66 | 1.55-4.58 | <.001 | 2.18 | 1.42-3.34 | <.001 | 32 | 1.48 | 0.82-2.66 | .194 |
. | OS from study entry . | EFS from study entry . | RR from end of course 2 . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
n . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | n . | HR . | 95% CI . | P . | |
HSF1-pSer326 | |||||||||||
Low | 52 | 1 | 1 | 48 | 1 | ||||||
Middle | 83 | 2.10 | 0.89-4.95 | .090 | 1.92 | 1.07-3.43 | .028 | 70 | 1.60 | 0.84-3.04 | .156 |
High | 69 | 3.58 | 1.56-8.22 | .003 | 2.94 | 1.65-5.24 | <.001 | 60 | 2.76 | 1.45-5.29 | .002 |
Risk group | |||||||||||
Low | 155 | 1 | 1 | 146 | 1 | ||||||
High | 49 | 2.66 | 1.55-4.58 | <.001 | 2.18 | 1.42-3.34 | <.001 | 32 | 1.48 | 0.82-2.66 | .194 |
HR, hazard ratio.